This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
HIV/AIDS	Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G (APOBEC3G; A3G); IL-15; toll-like receptor 2 (TLR2); TLR3; TLR9	A study in rhesus macaques suggests that adjuvants containing TLR agonists and IL-15 could help increase HIV vaccine efficacy. In a rhesus macaque model of simian immunodeficiency virus (SIV) infection, a vaccine adjuvanted with a combination of TLR2, TLR3 and TLR9 agonists and IL-15 boosted expression of host antiretroviral factor A3G and improved protection against SIV infection compared with vaccine alone or vaccine adjuvanted with only TLR agonists or IL-15. Next steps could include evaluating the adjuvant in combination with HIV vaccines. SciBX 3(21); doi:10.1038/scibx.2010.647 Published online May 27, 2010	Patent and licensing status unavailable	Sui, Y. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online May 10, 2010; doi:10.1073/pnas.0911932107 Contact: Jay A. Berzofsky, National Institutes of Health, Bethesda, Md. e-mail: berzofsj@mail.nih.gov Contact: Yongjun Sui, same affiliation as above e-mail: suiy@mail.nih.gov